Observational studyPharmaceutical research2022

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.

René J Boosman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.